ATROPISOMERS OF FLUORINATED TETRAPHENYLBACTERIOCHLORINS AND CHLORINS AND THEIR USE IN PHOTODYNAMIC THERAPY

• Main Authors: DA SILVA ARNAUT MOREIRA, Luís Guilherme, SCHABERLE, Fabio Antonio, CORREIA ALFAR, Sonia, FERREIRA GONÇALVES, Nuno Paulo, MIGUÉNS PEREIRA, Maria, PEREIRA MONTEIRO, Carlos Jorge, REIS DE ABREU, Artur Carlos, CERCA MARTINS DOS SANTOS, Tania Patricia, PEREIRA NASCIMENTO COSTA, Gonçalo
• Format: Patent
• Language: English; French; German
• Published: 08.01.2020
• Subjects: CHEMISTRY; HETEROCYCLIC COMPOUNDS; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

This invention relates to atroipsomers of reduced tetraphenylporphyrin derivatives with halogen atoms (F, Cl, Br) in the ortho positions of the phenyl groups, particularly halogenated tetraphenylchlorins and halogenated tetraphenylbacteriochlorins, which can be used in photodynamic therapy. According to the formulae of the invention, the ortho-phenyl substituents X1, X2, X3, X4, X5, X6, X7 and X8 may be identical or different and represent halogen atoms or hydrogen atoms, provided that at least all of X2, X4, X6 and X8 are halogens, and the meta-phenyl substituents R1, R2, R3 and R4 are independently chosen from -OH, -OR or -SO2R″, where R″ are each independently chosen from -Cl, -OH, -aminoacid, -OR, -NHR, or -NR2, where R are alkyl of 1 to 12 carbon atoms or R2 represents cycloalkyl with 2 to 12 carbon atoms. The atropisomers of this invention have the majority of the substituents R1, R2, R3 and R4 on the same side of the plane defined by the macrocycle. The invention also relates to an anticancer and/or antimicrobial and/or antiviral pharmaceutical composition where atropisomers α4 and α3β are the main active ingredients, such that the mixture of atropisomers α4 and α3β constitutes more than 70% of the atropisomers present in the active ingredient and/or the atropisomer α4 constitutes more than 20% of the atropisomers present in the pharmaceutical composition.